Protective immunity induced by a Trypanosoma cruzi soluble extract antigen in Experimental Chagas' Disease. Role of Interferon γ

CBA/J mice can be protected against lethal infection with Trypanosoma cruzi by treatment using T. cruzi soluble extract antigen (TCSE). In vivo administration of TCSE (400 μg/mouse) into naive mice increased the cellular proliferative response to Con A and elevated the levels of IFN-γ. The production of IFN-γ was extremely important in controlling the replication of the parasite since the protective activity of TCSE was completely abrogated by in vivo treatment with an anti IFN-γ neutralizing antibody. These results suggest that depending on the level, cytokine production results in the control of replication of the parasite in experimental Chagas'disease.

[1]  A. al‐Sabbagh,et al.  Evidence for cross-reactivity between antigen derived from Trypanosoma cruzi and myelin basic protein in experimental Chagas disease. , 1998, Experimental parasitology.

[2]  A. Ouaissi,et al.  Trypanosoma cruzi: analysis of cellular and humoral response against a protective recombinant antigen during experimental Chagas' disease. , 1995, Immunology letters.

[3]  L. Bermudez.  Production of transforming growth factor-beta by Mycobacterium avium-infected human macrophages is associated with unresponsiveness to IFN-gamma. , 1993, Journal of immunology.

[4]  S. Reed,et al.  Regulation of Trypanosoma cruzi infections in vitro and in vivo by transforming growth factor beta (TGF-beta) , 1991, The Journal of experimental medicine.

[5]  E. van Marck,et al.  Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice. , 1991, Journal of immunology.

[6]  M. Sztein,et al.  Trypanosoma cruzi reduces the number of high-affinity IL-2 receptors on activated human lymphocytes by suppressing the expression of the p55 and p70 receptor components. , 1989, Journal of immunology.

[7]  M. Sztein,et al.  Decreased human IL-2 receptor expression due to a protozoan pathogen. , 1989, Immunology today.

[8]  S. Reed,et al.  Immune deficiency in chronic Trypanosoma cruzi infection. Recombinant IL-1 restores Th function for antibody production. , 1989, Journal of immunology.

[9]  R. Coffman,et al.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens , 1988, The Journal of experimental medicine.

[10]  S. Reed.  In vivo administration of recombinant IFN-gamma induces macrophage activation, and prevents acute disease, immune suppression, and death in experimental Trypanosoma cruzi infections. , 1988, Journal of immunology.

[11]  A. Zlotnik,et al.  Enhancing effects of gamma interferon on phagocytic cell association with and killing of Trypanosoma cruzi , 1985, Infection and immunity.

[12]  A. Harel-Bellan,et al.  Modification of T-cell proliferation and interleukin 2 production in mice infected with Trypanosoma cruzi. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. E. Kuhn,et al.  Trypanosoma cruzi-induced suppression of the primary immune response in murine cell cultures to T-cell-dependent and -independent antigens. , 1980, The Journal of parasitology.

[14]  D. Snary,et al.  Protective immunisation of mice using cell surface glycoprotein from Trypanosoma cruzi , 1979, Nature.

[15]  I. Paulone,et al.  Experimental Chagas' disease: protective activity in relation with subcellular fractions of the parasite. , 1976, The Journal of parasitology.

[16]  E. Falcoff,et al.  Synergistic protection by specific antibodies and interferon against infection by Trypanosoma cruzi in vitro , 1984, European journal of immunology.